Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy
This article was originally published in PharmAsia News
Japan's well-defined regulatory framework for cell and regenerative therapies has notched up another "win" with the limited-use approval of a product for knee osteoarthritis, which should also generate useful new revenues for originator Cytori.
You may also be interested in...
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.
In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.